Abstract
The spleen tyrosine kinase Syk is an enigmatic protein tyrosine kinase functional in a number of diverse cellular processes. It is best known as a non receptor protein tyrosine kinase involved in signal transduction in cells of hematopoietic origin and plays a crucial role in signaling in most of these cells. It is involved in B and T-cell function, platelet aggregation, mast cell signaling, neutrophils and macrophages. Recently it has been found in tissues outside of the hematopoietic lineage. Perhaps the most interesting non-traditional role of Syk is that of a potential tumor suppressor in breast cancer. Absence of Syk protein in primary breast tumors is correlated with poor outcomes. Syk deficient cells have increased motility which is restored to normalcy by replacement with wild-type Syk. Syk also associates with the actin and tubulin cytoskeleton and is an α-tubulin kinase. The central role that Syk has in a number of cellular processes makes it an ideal starting point for broad therapeutic targeting.
Keywords: spleen tyrosine kinase, tyrosine kinase inhibitor, syk protein, breast tumors
Current Pharmaceutical Design
Title: The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Volume: 10 Issue: 15
Author(s): Christopher S. Navara
Affiliation:
Keywords: spleen tyrosine kinase, tyrosine kinase inhibitor, syk protein, breast tumors
Abstract: The spleen tyrosine kinase Syk is an enigmatic protein tyrosine kinase functional in a number of diverse cellular processes. It is best known as a non receptor protein tyrosine kinase involved in signal transduction in cells of hematopoietic origin and plays a crucial role in signaling in most of these cells. It is involved in B and T-cell function, platelet aggregation, mast cell signaling, neutrophils and macrophages. Recently it has been found in tissues outside of the hematopoietic lineage. Perhaps the most interesting non-traditional role of Syk is that of a potential tumor suppressor in breast cancer. Absence of Syk protein in primary breast tumors is correlated with poor outcomes. Syk deficient cells have increased motility which is restored to normalcy by replacement with wild-type Syk. Syk also associates with the actin and tubulin cytoskeleton and is an α-tubulin kinase. The central role that Syk has in a number of cellular processes makes it an ideal starting point for broad therapeutic targeting.
Export Options
About this article
Cite this article as:
Navara S. Christopher, The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy, Current Pharmaceutical Design 2004; 10 (15) . https://dx.doi.org/10.2174/1381612043384493
DOI https://dx.doi.org/10.2174/1381612043384493 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Computational Development of Selective nNOS Inhibitors: Binding Modes and Pharmacokinetic Considerations
Current Medicinal Chemistry Recent Progress in Synthesis and Applications of Fluorinated Carbohydrates
Current Organic Chemistry The Role of Neurogenesis in Neurodegenerative Diseases and its Implications for Therapeutic Development
CNS & Neurological Disorders - Drug Targets Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry Maternal Sepsis: Current Approaches to Recognition and Clinical Management
Current Women`s Health Reviews Anticancer Agents Derived from Natural Cinnamic Acids
Anti-Cancer Agents in Medicinal Chemistry Transcatheter Aortic Valve Implantation Infective Endocarditis: Current Data and Implications on Prophylaxis and Management
Current Pharmaceutical Design Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design Subject Index To Volume 6
Current Molecular Medicine Uptake and Metabolism of the Short-Chain Fatty Acid Butyrate, a Critical Review of the Literature
Current Drug Metabolism Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Design of multifunctional nanocarriers for delivery of anti-cancer therapy
Current Pharmaceutical Design The Design of Vectors for RNAi Delivery System
Current Pharmaceutical Design Recent Approaches for Studying the Role of Glia
CNS & Neurological Disorders - Drug Targets Effect of Binary Organic Solvents Together with Emulsifier on Particle Size and In vitro Behavior of Paclitaxel-Encapsulated Polymeric Lipid Nanoparticles
Current Drug Delivery Modulation of Tumour-Related Signaling Pathways by Natural Pentacyclic Triterpenoids and their Semisynthetic Derivatives
Current Medicinal Chemistry Brain Proton Magnetic Resonance Spectroscopy: A Review of Main Metabolites and its Clinical Applications in Gliomas
Current Molecular Imaging (Discontinued) Xenosensors CAR and PXR at Work: Impact on Statin Metabolism
Current Drug Metabolism p53: An Attractive Therapeutic Target for Cancer
Current Medicinal Chemistry Spherical Self-Organizing Map Detects MYBL 1 As Candidate Gene for Triple-Negative Breast Cancer
Neuroscience and Biomedical Engineering (Discontinued)